TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: biochemically-verified 7-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of diagnosis and therapeutic decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunologic Response (Antibody Responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pressure-time product of esophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of ropinirole extended release
Endpoint domain: Adverse events/effects
Primary endpoint: Degree and distribution of Y90 particle uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indocyanine green half life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral artery vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to significant change of antimicrobial therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nutritional sympathetic nervous system responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Breastfeeding self-efficacy of mothers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breastfeeding success of mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sucking success of newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyeblink conditioning performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of euploid embryos produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's Aggression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: LEQUESNE
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: GMT antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients eligible for treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Infection status after animal injury
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with positive response defined by eGFR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Death and Cause of Death
Endpoint domain: Mortality/survival
Primary endpoint: Change of serum 25OHD concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of CGM time in glucose range 70-180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucose tolerance (AUCgluc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verapamil mean total dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal pain recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self anxiety assessment scale (SAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with Adverse Events grade ≥3 related to LON002
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with Serious Adverse Events related to LON002
Endpoint domain: Adverse events/effects
Primary endpoint: status of professional reinsertion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Peak Plasma and Whole Blood Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Increased Iodine Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Visual Acuity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RANKL mRNA expression in the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death
Endpoint domain: Mortality/survival
Primary endpoint: postoperative CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postoperative hsTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PCL5 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BSI - Brief symptom inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WHO - QoL BREF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver Satisfaction Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of PD-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients reporting level C and above subjective symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Rating Using Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hamilton rating scale for depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Right Ventricular (RV) Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of biological specimen collections
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for re-intubation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Arteriovenous Fistulae Maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Arc of Flexion and Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Day of appearance of pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Measure impact on health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients at guideline goal for blood pressure and lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibrinogen degradation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early Childhood Caries (ECC) experience/prevalence at 3-years age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Early Childhood Caries (ECC) experience/prevalence at 6-years age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Incidences of Post-transplant Lymphoproliferative Disorder (PTLD)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidences of hospitalized infections
Endpoint domain: Adverse events/effects
Primary endpoint: Incidences of malignancy
Endpoint domain: Adverse events/effects
Primary endpoint: Transverse dimensional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bucco-lingual inclination changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jugular venous flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Epidermal re-epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changed Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of malignant diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Work Ability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Current employment status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Hospital Anxiety and Depression Scale; HADS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fear of Negative Evaluation (FNE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PASP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acute sexual arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of PD-related infections
Endpoint domain: Adverse events/effects
Primary endpoint: Unfractionated IFN-γ ELISpot responses to HIV-1 peptide pools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 and CD8 T cell responses to HIV-1 peptide pools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24-hour intraocular pressure (IOP) fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Performance on a Behavioral Approach Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PHC diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD39 and CD73-activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC-number and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Agreement Between CCS and NCEP Guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pediatric Evaluation of Disability Inventory (PEDICAT) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Timed Up and Go (TUG) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of de novo mutations detectable in father's sperm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Contact Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wheal diameter in the intradermal test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Achieved Seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dichotomized Histologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dichotomized Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in non-vellus hair count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With HbA1c Level Less Than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With At Least 5% Weight Loss From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients enrolling in clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Fatal Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: NCI CTCAE grade of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Detectable Human Papillomavirus (HPV) Antibody to Type 6 a Month After the Completion of HPV Vaccination Series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detectable Human Papillomavirus (HPV) Antibody to Type 11 a Month After the Completion of HPV Vaccination Series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detectable Human Papillomavirus (HPV) Antibody to Type 16 a Month After the Completion of HPV Vaccination Series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resting white and grey matter structural integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac structural integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Whole body fat and muscle quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived intensity of induced dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Skin Roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in quality of life specific for the gastrointestinal tract
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mindfulness positive awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brain activation in target region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-S/CGI-I
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IRLS
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: AUCinf of Filgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Filgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUEC0-t of ANC(absolute neutrophil count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Emax of ANC(absolute neutrophil count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cervical canal width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose tolerance test with estimation of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: quality of life - self estimation protocol
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: subjective responses to IV nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale (CAPS) Distressing Dream Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in CAPS PTS Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Nausea by Visual Analogue Scale (VAS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroparesis Cardinal Symptom Index -Daily Diary (GCSI-DD) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Half-gastric Emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety as assessed by clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of an osteo-articular infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Perception of medical condition as a taboo issue
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immediate Change in Headache Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the 6-item Headache Impact Test (HIT-6)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change in Serum Markers of Collagen Turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 90/90 hamstring length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Energy expenditure after physical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final Loss of the Restauration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean skeletal muscle mass measured by CT scan analysis at L3 area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean skeletal muscle mass measured by ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory System Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difficulty sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Secretions weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum plasma concentration of S-methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time of administration up to 24 hours post dosing of S-methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach the maximum plasma concentration of S-methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Accuracy Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional pharmacological uterotonic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of dystocia during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC0-t) of M3 Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of M3 Metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Acuity During Head Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal angle of spinal needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Harvard Trauma Questionnaire part IV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction of microflora amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: maintenance of healthy microflora amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: reduction of microflora variety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: maintenance of healthy microflora variety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Under-use of effective secondary stroke preventive measures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pharmacokinetics profile of lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of GH and IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lysholm-Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peace, Equanimity, and Acceptance in Cancer Experience (PEACE) Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kaldjian's Goals of Care at End of Life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Efficacy of Thymoglobuline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Security of Thymoglobuline
Endpoint domain: Adverse events/effects
Primary endpoint: Production of immunoglobulin A1, A2 and G totals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hip's range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Urinalysis-confirmed abstinence from opioids at 3 month follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalysis-confirmed abstinence from opioids at 6 month follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalysis-confirmed abstinence from opioids at 9 month follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalysis-confirmed abstinence from opioids at 12 month follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with gastroscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acetylcholinesterase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dopaminergic denervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes